Who are Intravenous sodium bicarbonate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): trisodium citrate, Experimental - 4% Sodium Bicarbonate, sodium bicarbonate 8.4%, Intensive treatment with sodium bicarbonate, Sodium Bicarbonate Solution, Sodium citrate/citratic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-sodium-bicarbonate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intravenous sodium bicarbonate — Competitive Intelligence Brief

Intravenous sodium bicarbonate (Intravenous sodium bicarbonate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkalinizing agent. Area: Critical Care / Toxicology / Metabolic Disorders.

marketed Alkalinizing agent Critical Care / Toxicology / Metabolic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous sodium bicarbonate (Intravenous sodium bicarbonate) — The Western Pennsylvania Hospital. Sodium bicarbonate acts as a buffer to neutralize excess acid in the blood and urine, raising pH to counteract acidosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous sodium bicarbonate TARGET	Intravenous sodium bicarbonate	The Western Pennsylvania Hospital	marketed	Alkalinizing agent
trisodium citrate	trisodium citrate	Onze Lieve Vrouwe Gasthuis	marketed	Anticoagulant / Alkalinizing agent	Ionized calcium (Ca2+)
Experimental - 4% Sodium Bicarbonate	Experimental - 4% Sodium Bicarbonate	Baptist Health South Florida	marketed	Antacid / Alkalinizing agent
sodium bicarbonate 8.4%	sodium bicarbonate 8.4%	University of Baghdad	marketed	Alkalinizing agent
Intensive treatment with sodium bicarbonate	Intensive treatment with sodium bicarbonate	University of Roma La Sapienza	marketed	pH modulator / alkalinizing agent
Sodium Bicarbonate Solution	Sodium Bicarbonate Solution	VA Greater Los Angeles Healthcare System	marketed	Alkalinizing agent
Sodium citrate/citratic acid	Sodium citrate/citratic acid	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	marketed	Urinary alkalinizing agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkalinizing agent class)

Hospital General "Dr. Miguel Silva" de Morelia · 1 drug in this class
Jennifer Gassman, PhD · 1 drug in this class
The Western Pennsylvania Hospital · 1 drug in this class
University of Baghdad · 1 drug in this class
VA Greater Los Angeles Healthcare System · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous sodium bicarbonate — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-sodium-bicarbonate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab